Skip to main content

Epilepsy Foundation, Intellimedix, Pfizer Partner on Personalized Epilepsy Drug Discovery

NEW YORK (GenomeWeb) – The Epilepsy Foundation has teamed with Pfizer and Intellimedix to create a drug discovery platform targeted toward patients with genetic forms of epilepsy, the foundation said today.

The partners hope the drug screening platform will be used to create individualized treatments for people with Dravet Syndrome, a severe form of genetic epilepsy, and for other types of this disease for which there are only limited treatment options.

Atlanta-based Intellimedix uses next-generation sequencing, predictive analytics, and in vitro animal models to discover, develop, validate, and repurpose drugs and diagnostics for epilepsy and other neurological disorders.

"This collaboration has the potential to benefit all individuals and families living with epilepsy, especially the one-third of people with epilepsy who live with uncontrolled seizures despite all currently available therapies," Epilepsy Foundation President and CEO Philip Gattone said in a statement.

The Scan

Gap in COVAX Doses

BBC News reports that COVAX is experiencing a vaccine shortfall, as the Serum Institute of India has paused exports.

Sanofi, GSK Report Promising Results

The Wall Street Journal reports that the candidate SARS-CoV-2 vaccine from Sanofi and GlaxoSmithKline has had encouraging early results.

Influence of Luck

The New York Times examines how the US avoided variant-fueled increases in COVID-19 cases.

PLOS Papers on Retina GWAS, Hantaan Virus, COVID-19 Phenome-Wide Association Study

In PLOS this week: genome-wide association study of retinal morphology, analysis of hantaan virus found in a mouse, and more.